Wall Street Zen began coverage on shares of Veradigm (NASDAQ:MDRX - Free Report) in a research report released on Tuesday. The brokerage issued a hold rating on the software maker's stock.
Separately, Stephens raised their price target on Veradigm from $7.00 to $13.00 and gave the company an "equal weight" rating in a research report on Friday, January 31st.
Read Our Latest Research Report on Veradigm
Veradigm Price Performance
Shares of NASDAQ:MDRX remained flat at $4.40 during trading on Tuesday. 7,004 shares of the stock were exchanged, compared to its average volume of 385,946. The company has a 50 day moving average price of $4.26 and a two-hundred day moving average price of $6.77. Veradigm has a 1 year low of $3.80 and a 1 year high of $11.80.
About Veradigm
(
Get Free Report)
Veradigm Inc, a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions.
Featured Articles
Before you consider Veradigm, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veradigm wasn't on the list.
While Veradigm currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
